Recent Finacing
Recent Raise
Carrick Therapeutics develops targeted oncology therapies—advancing CDK7 and CDK12/13 inhibitors including samuraciclib and a CDK12/13 glue-degrader—progressing hit-to-lead and lead optimization with Evotec-supported R&D in Dublin and Oxford.
